Clinical evaluation under MDR including CEP, CER, PMCF, and benefit-risk analysis.
INTRODUCTION
Clinical evaluation under the EU MDR is a systematic and continuous process by which a manufacturer demonstrates that a device placed or to be placed on the EU market meets the General Safety and Performance Requirements (GSPRs) in Annex I, performs as intended, and offers an acceptable benefit‑risk profile. The obligation to carry out clinical evaluation is set out in Article 61 and detailed in Annex XIV (Part A & B) of the Regulation.
REGULATORY BASIS & PURPOSE
Legal Foundation
Article 61 of the MDR states that the manufacturer “shall plan, conduct and document a clinical evaluation” to:
confirm conformity with the relevant GSPRs under normal conditions of intended use; and
Assess the acceptability of the benefit-risk ratio and any unwanted side effects.
Annex XIV – Part A sets out the specific requirements for the clinical evaluation process (planning, identification/appraisal of data, analysis, conclusions).
Annex XIV – Part B addresses the post‑market clinical follow‑up (PMCF) process as part of the clinical evaluation lifecycle.
Additional EU guidance such as MDCG 2020‑6 (“Sufficient clinical evidence for legacy devices”) and MDCG 2020‑5 (“Equivalence under MDR”) provide further interpretative support.
PURPOSE OF CLINICAL EVALUATION
The clinical evaluation process is designed to achieve:
Confirmation that the device meets the relevant GSPRs (Annex I) under its intended use.
Demonstration of safety and performance (including clinical benefits) supported by sufficient, valid clinical data.
Determination of an acceptable benefit‑risk profile, based on available clinical evidence.
Ongoing generation and reassessment of clinical evidence throughout the device lifecycle (pre‑ and post‑market).
In practice, the clinical evaluation is not a one‑time event but a continuous cycle of planning, collecting/appraising data, analysing, documenting, implementing PMCF where needed, and updating the evidence as the device is used in the market.
THE CLINICAL EVALUATION PROCESS
The process of clinical evaluation under EU MDR follows a logical sequence, structured in Annex XIV, Part A. The main steps are set out below.
Clinical Evaluation Plan (CEP)
Before data collection begins, the manufacturer must establish a detailed Clinical Evaluation Plan as per Annex XIV, Part A(1). Key elements include:
Definition of the device’s intended purpose, indications, target population, user and environment.
Identification of clinical benefits (direct or indirect) and relevant outcomes.
Definition of relevant GSPRs (Annex I) to which the device must conform.
Description of the literature search strategy, inclusion/exclusion criteria, databases, search terms, time frames.
Rationale for use of equivalence (if applicable) and justification for reliance on non‑clinical data or literature.
Integration of the plan with the manufacturer’s quality management system (QMS) and risk management file (per ISO 14971).
Where new clinical investigations are required, alignment with standards such as ISO 14155:2020.
Guidance emphasises that the CEP must clearly define objectives, methods, criteria and that it be justifiable, reproducible, and appropriately documented.
Identification and Appraisal of Clinical Data
Once the plan is in place, manufacturers must identify all relevant clinical data. This includes:
Published scientific literature (peer‑reviewed journals, meta‑analyses).
Data from manufacturer‑sponsored or independent clinical investigations.
Post‑market surveillance (PMS) and PMCF data, real‑world clinical experience, registries, complaint/failure databases.
If relevant, data from equivalent devices (subject to strict conditions under MDR).
The identified data must then be appraised for relevance, reliability, methodological soundness, scientific validity (including sample size, bias controls, follow‑up duration) and applicability to the device, its indications and its user population.
Manufacturers should use structured tools (e.g., PICO frameworks, risk‑of‑bias checklists, hierarchy of evidence) to ensure robust appraisal.
Generation of New Clinical Data
If the existing data are insufficient to demonstrate conformity with the GSPRs and the benefit‑risk profile, manufacturers must conduct new clinical investigations in accordance with Article 62 to 82 and Annex XV of the MDR. For high‑risk (Class III) and implantable devices, or novel technologies, this is often mandatory unless equivalence is demonstrably robust. The new data must be collected according to good clinical practices (e.g., ISO 14155) and appropriately reported.
Analysis and Benefit‑Risk Determination
With the data gathered and appraised, the manufacturer must analyse the combined clinical evidence to:
Confirm that the device performs as intended and meets its claimed clinical benefits.
Demonstrate that the residual risks are acceptable in light of the benefits (benefit‑risk profile).
Map clinical findings to the GSPRs and risk management file, ensuring traceability between identified risks and clinical outcomes.
Address device variants, accessories, lifetime of use, user population sub‑groups, and any untreated indications. Guidance emphasises that conclusions must be device‑specific, indication‑specific, and population‑specific.
The manufacturer’s conclusion should clearly state whether the evidence is sufficient, what gaps exist (if any), and what residual uncertainties remain.
Clinical Evaluation Report (CER)
The outcomes of the evaluation must be documented in a Clinical Evaluation Report (CER). The CER should:
Summarise the plan, data sources, appraisal methodology, analysis, conclusions and updates.
Demonstrate linkage to the device’s technical documentation, risk management file, and PMS/PMCF data.
Include favourable and unfavourable data (full transparency).
Be signed by a qualified evaluator and be part of the technical documentation submitted to the Notified Body (NB) during conformity assessment. Guidance (e.g., MDCG 2020‑13) provides templates and expected content for CERs.
Be updated throughout the life of the device whenever new relevant data become available (lifecycle maintenance).
EQUIVALENCE AND ITS CHALLENGES
Under MDR, manufacturers may rely on clinical data from an equivalent device only if strict criteria are met. Annex XIV, Part A(3) states this.
Conditions for equivalence include:
Demonstrated equivalence in technical, biological, and clinical characteristics.
Full access to the technical documentation of the equivalent device, including design, manufacturing process, materials, sterilisation, biological safety, residual risks.
The equivalent device must itself conform to MDR clinical evaluation requirements.
Because of the high bar, many manufacturers find equivalence claims difficult to justify and Notified Bodies often request clinical investigations instead of equivalence‑based justification.
POST‑MARKET CLINICAL FOLLOW‑UP (PMCF) & LIFECYCLE APPROACH
PMCF Requirements
The MDR requires that clinical evaluation be maintained throughout the product lifecycle. Annex XIV, Part B specifies PMCF activities and reporting obligations. Key PMCF activities include:
Regularly updating literature searches and published data analyses.
Collecting clinical experience from use in real life (registries, surveys, observational studies).
Identifying and analysing new or emerging risks, verifying continued acceptability of benefit‑risk ratio.
Considering off‑label use, misuse, incremental modifications, new user populations, accessories.
The manufacturer must document a PMCF Plan and a PMCF Evaluation Report; the latter forms part of the CER.
Lifecycle Maintenance Of Clinical Evaluation
Under Article 61(12), the manufacturer must keep clinical evidence up to date. High‑risk/implantable devices typically require at least annual review; lower‑risk devices should have reviews based on risk and PMS outcomes. Guidance emphasises that clinical evaluation is a living document.
Updates should include: changes to device design or indications, new clinical data, corrective actions triggered by PMS, emerging technological alternatives (state‑of‑the‑art), or regulatory intelligence.
COMMON PITFALLS AND COMPLIANCE RISKS
Manufacturers often encounter the following issues:
Inadequate literature search: not systematic, not reproducible, missing grey literature or scientific databases. This weakens the credibility of the CER.
Weak appraisals: failing to assess methodological quality, bias, statistical robustness or to map data to GSPRs and risks.
Equivalence claims without full documentation access: Notified Bodies frequently reject equivalence justification when the manufacturer cannot fully document equivalence.
Insufficient new clinical data when needed: For novel devices, relying solely on literature or equivalence may not suffice.
Poor linkage between risk management and clinical evaluation: The CER must reference residual risks identified in the risk file and show how clinical evidence addresses them.
Neglecting PMCF integration: Some manufacturers treat clinical evaluation as a pre‑market activity only; MDR requires ongoing updates and integration with post‑market surveillance.
Documentation lapses: The CEP and CER must be properly version‑controlled, dated, signed, incorporated into the QMS.
Avoiding these issues requires cross‑functional integration (regulatory, clinical, quality, manufacturing), clear version management, robust methodologies for literature/data appraisal, and proactive planning for lifecycle evidence generation.
KEY TAKEAWAYS FOR MANUFACTURERS
Clinical evaluation is mandatory for all devices under MDR (Article 5(3) in conjunction with Article 61 and Annex XIV).
It is a continuous lifecycle activity, not a one‑time event.
The CEP sets the roadmap; the CER documents the justification and conclusions.
Evidence must be device‑specific, indication‑specific and reflect the target population and user environment.
Equivalence is permissible only under stringent conditions; many firms must rely on new clinical data.
PMCF and life‑cycle maintenance ensure that the device remains safe and performs as intended after market entry.
Align your clinical evaluation process with the latest guidance (MDCG 2020‑6, MDCG 2020‑5, MDCG 2020‑13) and ensure that your internal QMS reflects these expectations.
CONCLUSION
In today’s regulatory environment under EU MDR 2017/745, a well‑executed clinical evaluation is not simply a regulatory checkbox. It is a strategic document that supports market access, patient safety, and the device’s ongoing value proposition. Manufacturers who integrate the clinical evaluation into their quality management and post‑market surveillance framework will stand in a stronger position when engaging with Notified Bodies and maintaining compliance across the device lifecycle.
HOW MORULAA CAN HELP
Morulaa supports manufacturers through the entire clinical evaluation process under EU MDR 2017/745. We assist in preparing Clinical Evaluation Plans (CEP), conducting systematic literature reviews, evaluating equivalence, and drafting Clinical Evaluation Reports (CER) aligned with Article 61 and Annex XIV. Our team ensures data traceability to GSPRs, develops PMCF plans, and provides lifecycle updates for high-risk devices. With expertise in ISO 14155 and MDR-compliant documentation, Morulaa helps streamline your CE marking process and ensures readiness for Notified Body review.
